Clovis Oncology and Avila Therapeutics to Collaborate on Novel Lung Cancer Drug
Debbie Tranter
Abstract
Clovis Oncology Inc will pay up to USD 209 M for joint development of Avila Therapeutics’ innovative treatment for non-small cell lung cancer (NSC
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.